Products

Product for Out-licensing

A A A

  • Overview
  • Product Profile
  • News

AdvaTab® Paracetamol (acetaminophen) ODT

Pain
AdvaTab

Eurand’s premier orally disintegrating tablet (ODT) formulation of paracetamol (also widely known as acetaminophen) provides this leading analgesic in a convenient ODT dosage form formulated in a range of dosing strengths for pediatrics and adults.


Eurand uses their proprietary Microcaps® taste-masking and AdvaTab® ODT technologies to create an easy-to-swallow dose with excellent taste and no grittiness. Eurand’s ODTs disintegrate in less than 30 seconds and can be taken as needed, with or without water.

This combination of Eurand technologies has been successfully commercialized in products around the world, including Chattem’s Unisom® SleepMelts and GSK’s Lamictal® ODT.

Therapeutic Category

Pain

Indication

Mild analgesic used to relieve headache, fever, muscle and body pain, arthritis, and joint pain

Development Status

USP Monograph OTC: Ready to launch

Available Dosage Strength(s)

80 mg - 500 mg

Product Description

Orally disintegrating tablet (ODT) formulation of paracetamol (also widely known as acetaminophen)

Eurand Technology

  • AdvaTab® - Orally Disintegrating Tablet (ODT) technology
  • Microcaps® - Taste-masking technology

Licensing Opportunities

USP Monograph OTC: Ready to launch in U.S.

Marketing authorizations are available in a number of EU major markets.

Additional territories may be added upon consultation with our partners.

Latest News:


07/20/2009

Eurand Successfully Completes Registration Procedure for Paracetamol ODT 250 and 500 mg in the European Union

Eurand announced today that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500 mg Orodispersible Tablets (ODT) in several EU countries has been successfully completed.

This information is provided solely for the purpose of the evaluation of business opportunities by potential collaboration partners. The information is based on currently existing data and marketing authorizations in a number of jurisdictions and should not be assumed to be approved by regulatory authorities in any individual country. Consumers should consult with their individual physician for product information and should not rely upon any information provided here.

For more information on this product, please contact Eurand.

The information contained in this document is for Ex-U.S. use only.
Please confirm that you are downloading this document for Ex-U.S. use.